Showing 11-20 of 28 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Quality, Equity & Outcomes Program | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-September-2026 to 31-August-2028 | $1.400.000,00 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-December-2026 | $1.808.522,70 |
| Differential Aptalyzer: a wearable hydrogel microneedle platform for continuous monitoring of C-peptide in vivo | New York University | Mahla Poudineh | Cures | 01-November-2026 to 31-October-2029 | $997.957,86 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2027 | $750.000,00 |
| T1D Data Identification Consensus Initiative | Milliman | Rebecca Smith | Cures | 15-September-2026 to 31-May-2027 | $260.000,00 |
| Autoimmune stem-like T cells in type 1 diabetes | Memorial Sloan-Kettering Cancer Center | Andrea Schietinger | Cures | 01-September-2023 to 31-August-2026 | $750.000,00 |
| Bringing Beta Cell Regenerative Therapy to the Clinic | Icahn School of Medicine at Mount Sinai | Andrew Stewart | Cures | 01-January-2024 to 31-December-2026 | $1.000.000,00 |
| Exploring the Effects of Beta Cell Regenerative Drugs on Cell Fate Decisions in Human Pancreatic Islets | Icahn School of Medicine at Mount Sinai | Esra Karakose | Cures | 01-March-2025 to 28-February-2030 | $999.999,00 |
| Targeting pathogenic Th17 cells as shared mechanisms in MS, SLE and T1D | Icahn School of Medicine at Mount Sinai | Ka Lung Cheung | Cures | 01-September-2026 to 31-August-2027 | $149.950,03 |
| Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy | Icahn School of Medicine at Mount Sinai | Peng Wang | Cures | 01-July-2025 to 31-December-2026 | $305.000,00 |